Luteolin attenuates the chemoresistance of osteosarcoma through inhibiting the PTN/β-catenin/MDR1 signaling axis by upregulating miR-384
Multidrug resistance (MDR) remains a critical bottleneck in successful treatment of osteosarcoma (OS). Luteolin is a flavonoid compound that has been verified to increase the sensitivity to antineoplastic drugs in many tumors. However, its roles in reversing MDR of OS and the potential underlying me...
Gardado en:
| Principais autores: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Elsevier
2022-06-01
|
| Series: | Journal of Bone Oncology |
| Assuntos: | |
| Acceso en liña: | http://www.sciencedirect.com/science/article/pii/S2212137422000197 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|